Paradigm Biopharmaceuticals Limited (ASX:PAROA)
Australia · Delayed Price · Currency is AUD · Option0.0010
-0.0010 (-50.00%)
At close: Feb 5, 2026
Paradigm Biopharmaceuticals Company Description
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia.
Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases.
The company was incorporated in 2014 and is headquartered in Melbourne, Australia.
Paradigm Biopharmaceuticals Limited
| Country | Australia |
| Founded | 2014 |
| Industry | Biological Products, Except Diagnostic Substances |
| CEO | Paul Rennie |
Contact Details
Address: 500 Collins Street Melbourne, 3000 Australia | |
| Phone | 61 3 9629 5566 |
| Website | paradigmbiopharma.com |
Stock Details
| Ticker Symbol | PAROA |
| Exchange | Australian Securities Exchange |
| Stock Type | Option |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Paul Rennie | Chief Executive Officer |
| Abby Macnish Niven | Chief Financial Officer |
| Simon White | Head of Investor Relations |